Virus-Free Sf9 Cell Lines via Antiviral Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell lines used in bioproduction, such as those derived from Spodoptera frugiperda and Trichoplusia ni, are often contaminated with viruses like Sf-rhabdovirus and Tn-nodavirus, posing challenges for the production of safe and effective vaccines and biologics.
Innovation Solution
Development of virus-free established cell lines, such as Sf-RVN and Tn-NVN, obtained through isolation and treatment with antiviral compounds, which are characterized by their ability to grow and produce recombinant proteins similar to their virus-contaminated counterparts but without viral contamination, using methods that include isolating cells, treating them with antiviral drugs, and testing for viral absence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If virus-contaminated cell lines are used for bioproduction, then productivity and ease of manufacture are improved, but safety and purity deteriorate due to viral contamination
Solution Approach 1:
The patent applies preliminary action by treating cells with antiviral compounds during the culture process before viral contamination can occur or spread. This preventive treatment ensures that the cell lines remain virus-free throughout bioproduction, eliminating the need for post-production viral testing and purification steps while maintaining continuous productivity.
Solution Approach 2:
The patent converts the harmful effect of antiviral compounds (which can inhibit cell growth) into a benefit by using them to eliminate viral contamination. The selective pressure from antiviral treatment eliminates virus-infected cells while allowing virus-free cells to thrive, thereby transforming a potentially harmful substance into a tool for ensuring product safety and purity.
2Object-affected harmful factors
If antiviral treatment is applied to eliminate viral contamination, then purity and safety are improved, but cell growth and productivity may deteriorate
Solution Approach 1:
The patent applies parameter changes by optimizing the concentration, duration, and timing of antiviral compound treatment to achieve viral elimination while minimizing impact on cell growth. By carefully controlling these parameters, the treatment effectively removes viruses without causing significant toxicity or growth inhibition to the host cells, thus maintaining productivity.
Solution Approach 2:
The patent uses antiviral compounds as intermediaries that selectively target viral processes without directly harming host cell functions. These compounds act as mediators that interfere with viral replication and propagation while allowing normal cell metabolism and protein production to continue, thereby eliminating viruses while preserving productivity.
3Ease of operation
If established cell lines are used instead of primary cells, then productivity and ease of operation are improved, but reliability deteriorates due to genetic abnormalities and viral contamination
Solution Approach 1:
The patent applies preliminary action by establishing virus-free cell lines through antiviral treatment and screening before they are used for continuous culture. This upfront preparation ensures that the cell lines are genetically stable and free from viral contamination, maintaining reliability throughout long-term continuous operation while preserving the operational advantages of established cell lines.
Solution Approach 2:
The patent converts the genetic abnormalities and viral contamination inherent in established cell lines into benefits by using antiviral treatment and selection processes. These processes eliminate virus-infected and genetically unstable cells, enriching the population for healthy, stable cells. Thus, the very characteristics that make established cell lines problematic become opportunities for selecting improved, reliable cell lines.
Data Source
AI summary
The current teachings are directed to novel virus free cells lines derived from virus-contaminated staring material, such as an organism or a cell line. Methods for obtaining virus free cell lines obtained from virus-contaminated starting material are also provided. Exemplary virus free cell lines include: novel cell lines derived from a Spodoptera frugiperda cell line contaminated with Sf-rhabdovirus, wherein the novel cell lines lack Sf-rhabdovirus; and novel cell lines derived from a Trichoplusia ni cell line contaminated with an alphanodavirus, wherein the novel cell line lacks an alphanodavirus.